<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210502051162N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-25</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Therapy with low level Laser therapy in patients under methadone maintenance treatment</public_title>
      <acronym></acronym>
      <scientific_title>Therapeutic effects of low level Laser therapy in reducing anxiety, depression, and substance abuse craving in patients under methadone maintenance treatment Compared with the control group</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56050</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly divided into two groups. The randomization tool used will be a table of random numbers. In order to randomize, a random block method will be used. For this purpose, we formed blocks of size 8. In each block, 4 individuals will be in intervention group and 4 will be in control group. A total of 10 blocks will be considered for the study.
It will be used to blinding, similar devices without labels and only with code. In the intervention group, patients will be treated with a low level laser device, and in the control group, the device will be on their head, but it will be off, Blinding description: Clinical caregivers and patients will be unaware and blind to the type of treatment. It will be used to hide similar devices, without labels and only with code. In the intervention group, patients will be treated with a low level light device, and in the control group, the device will be on their head, but it will be off. Patients will be aware that they will be randomly assigned to one of the two treatment groups, but will not know which treatment will be offered in that group. Patients will be placed in one of two groups using a random number table. The clinician also knows that patients will be treated in two different ways, but will not know which method will work for each patient. The data collector, analyst and outcome assessor will collect and analyze information based on groups 1 and 2, and will not be aware of the type of treatment provided in the groups. They will be kept blind.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Addiction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: This group is treated with low level Laser therapy for 2 weeks and 3 sessions per week. The time of exposure to light is 4 minutes in both places of the forehead. This treatment involves the use of a light emitting diode with a maximum wavelength of 810 nm with a full width of up to 40 nm. Creates radiation of 250 mW/cm2 when applied to 4 mm of skin. Intervention 2: Control group: In this group, the laser device is on their head but it is off. They are placed under the device for 2 weeks and 3 sessions every week. Are placed. The time to stay under the device is 4 minutes in both places of the forehead.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only part of the data such as information about the main outcome or the like can be shared.

When:
Access period starts 6 months after the results are published

To whom:
Our data will only be available to researchers working in academia

Conditions:
Any statistical analysis is allowed

Where to obtain:
helia helali
09127103907
heliahelali1990@yahoo.com

How to obtain:
Upon request, information will be sent via email or phone as soon as possible

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Helia Helali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fereshteh, Bosnia-Herzegovina Street, Koohyar Street, Second Dead End, No. 22.Bell 4 East</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1965715551</zip>
        <telephone>+98 21 2205 7254</telephone>
        <email>heliahelali1990@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>helia helali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fereshteh, Bosnia-Herzegovina St., Koohyar St., Second Dead End No. 22  4 East</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1965715551</zip>
        <telephone>+98 21 2205 7254</telephone>
        <email>heliahelali1990@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients on methadone treatment who have been in treatment for at least three months
Age over 18 years
Admission will be regardless of gender or ethnicity</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients treated with other methods of quitting addiction
Methadone maintenance treatment less than 3 months
We excluded patients who were not between the ages of 18 and 60
Anyone with a history of psychosis and other psychiatric disorders (bipolar, etc.)
A history of violent behavior, a history of moving or attempting suicide in the past</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Opioid related disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: This group is treated with low level Laser therapy for 2 weeks and 3 sessions per week. The time of exposure to light is 4 minutes in both places of the forehead. This treatment involves the use of a light emitting diode with a maximum wavelength of 810 nm with a full width of up to 40 nm. Creates radiation of 250 mW/cm2 when applied to 4 mm of skin.</i_keyword>
      <i_keyword>Control group: In this group, the laser device is on their head but it is off. They are placed under the device for 2 weeks and 3 sessions every week. Are placed. The time to stay under the device is 4 minutes in both places of the forehead.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety rate. Timepoint: After the end of treatment and one month after the last treatment. Method of measurement: HAM-A Through a questionnaire (Hamilton Anxiety measure scale).</prim_outcome>
      <prim_outcome>Depression rate. Timepoint: After the end of treatment and one month after the last treatment. Method of measurement: HAM-D Through a questionnaire (Hamilton depression measure scale).</prim_outcome>
      <prim_outcome>Opioid craving scale. Timepoint: After the end of treatment and one month after the last treatment. Method of measurement: OCS  Through a questionnaire  (opioid craving scale).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-06-07</approval_date>
        <contact_name>Ethics Committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Tehran, Evin, Shahid Shahriari Square Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
